Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
ABAbivax S.A. logo

Abivax S.A. (ABVX)

NASDAQ Global Market · Currency in USD
$88.01 ▼ -2.22 (-2.46%)
At close: Oct 23, 4:00 PM ET. Market closed.
$87.56 ▼ -0.45 (-0.51%)
After hours: Oct 23, 7:56 PM ET

Summary

Previous Close
$90.23
Open
$89.60
Day's Range
$87.02 – $89.60
52 Week Range
$69.81 – $148.83
Volume
432,466
Avg. Volume
1,404,839
Market Cap
$7.68B
Beta (5Y Monthly)
-0.25
PE Ratio (TTM)
--
EPS (TTM)
-$4.43
Earnings Date
Dec 21, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$156.00

Profile: Abivax S.A.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
80
CEO
Marc de Garidel
Website
abivax.com

Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV.

Earnings

Next report: Mon, Dec 21, 2026
EPS estimate -$0.92 · Revenue est. $768.79K
DateEst.Actual
Sep 21, 2026-$0.98-$1.71Miss
May 22, 2026-$1.07-$0.71Beat
Mar 23, 2026-$1.70-$1.19Beat
Dec 15, 2025-$0.79-$2.47Miss
Sep 8, 2025-$0.90-$0.86Beat
Jun 2, 2025-$0.76-$0.97Miss

Analyst view

Consensus price target
$156.00 ▲ +77.3%
Range $118.00 – $180.00
Rating: Buy
Buy 92% · Hold 8% · Sell 0%

Get free alerts on ABVX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.